Jacobs & Co. CA increased its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 3.5% during the second quarter, Holdings Channel reports. The firm owned 82,926 shares of the pharmaceutical company’s stock after buying an additional 2,833 shares during the period. Jacobs & Co. CA’s holdings in GlaxoSmithKline PLC were worth $3,575,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the stock. Koshinski Asset Management Inc. boosted its stake in shares of GlaxoSmithKline PLC by 5.6% in the first quarter. Koshinski Asset Management Inc. now owns 10,011 shares of the pharmaceutical company’s stock valued at $422,000 after buying an additional 527 shares during the period. Dynamic Advisors Solutions LLC boosted its stake in shares of GlaxoSmithKline PLC by 1,411.4% in the first quarter. Dynamic Advisors Solutions LLC now owns 95,292 shares of the pharmaceutical company’s stock valued at $4,017,000 after buying an additional 88,987 shares during the period. Augustine Asset Management Inc. boosted its stake in shares of GlaxoSmithKline PLC by 23.6% in the first quarter. Augustine Asset Management Inc. now owns 17,585 shares of the pharmaceutical company’s stock valued at $741,000 after buying an additional 3,355 shares during the period. GW&K Investment Management LLC boosted its stake in shares of GlaxoSmithKline PLC by 17.8% in the first quarter. GW&K Investment Management LLC now owns 1,017,202 shares of the pharmaceutical company’s stock valued at $42,885,000 after buying an additional 153,555 shares during the period. Finally, Raymond James Trust N.A. boosted its stake in shares of GlaxoSmithKline PLC by 3.4% in the first quarter. Raymond James Trust N.A. now owns 132,266 shares of the pharmaceutical company’s stock valued at $5,576,000 after buying an additional 4,401 shares during the period. Hedge funds and other institutional investors own 8.96% of the company’s stock.
Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 42.66 on Friday. The stock has a market capitalization of $104.22 billion, a P/E ratio of 48.48 and a beta of 1.04. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $45.58. The stock’s 50 day moving average is $43.28 and its 200-day moving average is $41.70.
GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 26th. The pharmaceutical company reported $0.62 EPS for the quarter, meeting analysts’ consensus estimates of $0.62. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. The company had revenue of $9.23 billion during the quarter, compared to analyst estimates of $9.09 billion. On average, equities research analysts expect that GlaxoSmithKline PLC will post $2.86 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 13th. Shareholders of record on Friday, May 12th were paid a dividend of $0.483 per share. The ex-dividend date was Wednesday, May 10th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.93 dividend on an annualized basis and a yield of 4.53%. GlaxoSmithKline PLC’s dividend payout ratio is currently 233.74%.
TRADEMARK VIOLATION WARNING: This news story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2017/07/22/glaxosmithkline-plc-nysegsk-position-raised-by-jacobs-co-ca.html.
Several brokerages recently commented on GSK. ValuEngine cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Friday, June 16th. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Citigroup Inc. cut shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Finally, Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $46.00.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
